A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer’s disease
Christopher Maas, Laura Fang, Elke Mathey, Christian Jacob, Timotheus Stremel, Tammo Viering, Roland Fliedner, Marlena Schnieder, Christine A. F. von Arnim · 2026
Read A comprehensive German claims data analysis of care pathways, risk factors and comorbidities among acetylcholinesterase inhibitor initiators in Alzheimer’s disease by Christopher Maas, Laura Fang, Elke Mathey, Christian Jacob, Timotheus Stremel, Tammo Viering, Roland Fliedner, Marlena Schnieder, Christine A. F. von Arnim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13529785.txt.
Description
Christopher Maas and eight co-authors trace the care of Alzheimer's patients in German insurance data in a 2026 study. They focus on people starting a common first-line drug class, used as a stand-in for early disease.
Two groups were built: about 2,000 starters tracked for eight years before treatment, and about 2,050 tracked for five years after. Mobility problems rose by 55 percent in the years before the first prescription. Eight years out, about 82 percent of future patients already had a changeable risk factor, more than matched controls. Advanced tests were rare in the year before treatment: MRI for 39 percent, spinal fluid tests for under 10 percent. The study shows late and patchy diagnosis in routine care.
Catalog record
| CREATOR | Christopher Maas, Laura Fang, Elke Mathey, Christian Jacob, Timotheus Stremel, Tammo Viering, Roland Fliedner, Marlena Schnieder, Christine A. F. von Arnim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |